Abiopharma

FOXO TECHNOLOGIES INC.’S CRITICAL ACCESS HOSPITAL ANNOUNCES NEW WOUND CARE SERVICES OFFERING

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

New Form 8-K - Surgery Partners, Inc. Filed: 2025-06-17 AccNo: 0001638833-25-000117 Size: 329 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

A New Press Release from Elicio Therapeutics

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Quantum-Si Customer to Showcase Protein Barcoding for NucleicAcid–LNP Therapeutic Development at Festival of Genomics Boston

New Form 8-K - Marker Therapeutics, Inc. Filed: 2025-06-17 AccNo: 0001104659-25-060092 Size: 217 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Aptose Biosciences Inc. Filed: 2025-06-17 AccNo: 0001171843-25-003935 Size: 194 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives

New Form 6-K - Quantum Biopharma Ltd. Filed: 2025-06-17 AccNo: 0001171843-25-003936 Size: 15 KB

New Form 8-K - Ventyx Biosciences, Inc. Filed: 2025-06-17 AccNo: 0000950170-25-087068 Size: 275 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Allurion - Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering